DDIT3 and diffuse large B-cell lymphoma: A phase Ib trial of ibrutinib plus R-CHOP showed that ibrutinib and R-CHOP did not affect each other’s pharmacokinetics, that ibrutinib is well tolerated when added to R-CHOP, and that all 18 patients with DLBCL who received the recommended phase 2 dose had an overall response31.